Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
暂无分享,去创建一个
I Kimber | G. Orphanides | J. Moggs | I. Kimber | G Orphanides | D. J. Moore | F. Lim | T. C. Murphy | R. Stuckey | K. Antrobus | J G Moggs | T C Murphy | F L Lim | D J Moore | R Stuckey | K Antrobus
[1] B. van der Burg,et al. Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. , 1989, Molecular and cellular endocrinology.
[2] E. Lobenhofer,et al. Regulation of DNA replication fork genes by 17beta-estradiol. , 2002, Molecular endocrinology.
[3] Steven C. Lawlor,et al. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways , 2002, Nature Genetics.
[4] R. Sutherland,et al. Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.
[5] J. Blow,et al. Replication licensing — Origin licensing: defining the proliferative state? , 2002 .
[6] C. Klinge. Estrogen receptor interaction with estrogen response elements. , 2001, Nucleic acids research.
[7] S. Reed,et al. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover , 2003, Nature Reviews Molecular Cell Biology.
[8] A. Philips,et al. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. , 1998, Molecular endocrinology.
[9] D. Coppock,et al. The quiescin Q6 gene (QSCN6) is a fusion of two ancient gene families: thioredoxin and ERV1. , 1998, Genomics.
[10] Barry Komm,et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.
[11] J. Laborda,et al. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. , 1991, Nucleic acids research.
[12] B. Katzenellenbogen,et al. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells , 1999, Molecular and Cellular Endocrinology.
[13] K. Kinzler,et al. A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Blow,et al. Replication licensing--defining the proliferative state? , 2002, Trends in cell biology.
[15] H. Rochefort,et al. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .
[17] Guoying Liu,et al. NetAffx: Affymetrix probesets and annotations , 2003, Nucleic Acids Res..
[18] E. Lobenhofer,et al. Regulation of DNA Replication Fork Genes by 17β-Estradiol , 2002 .
[19] John H. White,et al. Genome-wide identification of high-affinity estrogen response elements in human and mouse. , 2004, Molecular endocrinology.
[20] J. Bard,et al. Ontologies in biology: design, applications and future challenges , 2004, Nature Reviews Genetics.
[21] J. Herman,et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.
[22] M. Pike,et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.
[23] S. Baylin,et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.
[24] Patricia A. Dyck,et al. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. , 2002, Cancer research.
[25] Adrian V. Lee,et al. Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. , 2003, Cancer research.
[26] H. Rochefort,et al. How to target estrogen receptor-negative breast cancer? , 2003, Endocrine-related cancer.
[27] K. Korach,et al. The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling* , 2001, The Journal of Biological Chemistry.
[28] V. Giguère,et al. Coregulators of estrogen receptor action. , 2002, Critical reviews in eukaryotic gene expression.
[29] E. Gelmann,et al. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. , 1986, Cancer research.
[30] Carlos S. Moreno,et al. MTA3, a Mi-2/NuRD Complex Subunit, Regulates an Invasive Growth Pathway in Breast Cancer , 2003, Cell.
[31] S. Baylin,et al. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.
[32] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[33] J. Herman,et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. , 2000, Cancer research.
[34] H. Vodermaier. Cell cycle: Waiters serving the Destruction machinery , 2001, Current Biology.
[35] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[36] M. Hatano,et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] G. Orphanides,et al. Characterisation of the molecular responses to xenoestrogens using gene expression profiling , 2002, Phytochemistry Reviews.
[38] F. Bresciani,et al. Estrogen stimulates transcription of c-jun protooncogene. , 1990, Molecular endocrinology.
[39] U. Thorgeirsson,et al. Altered Localization of Retinoid X Receptor α Coincides with Loss of Retinoid Responsiveness in Human Breast Cancer MDA-MB-231 Cells , 2004, Molecular and Cellular Biology.
[40] P. Chambon,et al. Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[41] V. Jordan,et al. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines , 1994, The Journal of Steroid Biochemistry and Molecular Biology.
[42] Myles Brown,et al. Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.
[43] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[44] Preventing hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.
[45] T. Ozaki,et al. Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of the entry into the S phase. , 1995, Cancer research.
[46] P. Argos,et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A , 1986, Nature.
[47] Neil J. McKenna,et al. Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.
[48] M. Campiglio,et al. Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.
[49] G. Orphanides,et al. Estrogen receptors: orchestrators of pleiotropic cellular responses , 2001, EMBO reports.